CTH-300: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson#s Disease Complicated by Motor Fluctuations (#OFF# Episode

Grants and Contracts Details

StatusFinished
Effective start/end date5/4/177/9/18

Funding

  • Sunovion Pharmaceuticals Incorporated: $31,051.00